Most people with chronic hepatitis B enrolled in a Phase 2b clinical trial were eligible to discontinue their use of standard antiviral medication six…
News
CHOLANGITIS
NewsFDA approves seladelpar, now Livdelzi, to treat adults with PBC
Note: This story was updated Aug. 20, 2024, to correct that Livdelzi is not a first-in-class therapy for primary biliary cholangitis. The U.S. Food…
CHOLANGITIS
NewsTriple treatment combo works best for UDCA-resistant PBC: Study
A triple treatment combination adding fibrates — a type of medication that has shown promise in primary biliary cholangitis (PBC) — to dual therapy…
CHOLESTASIS
NewsCase study supports safety, efficacy of liver transplant for PFIC3
A 3-year-old boy with progressive familial intrahepatic cholestasis type 3 (PFIC3) was safety and effectively treated with a liver transplant from his mother after failing…
FATTY LIVER DISEASE
NewsTwo Phase 3 pegozafermin trials for severe fatty liver disease enrolling
Two Phase 3 clinical trials testing pegozafermin in people with metabolic dysfunction-associated steatohepatitis (MASH), a severe manifestation of fatty liver disease, are enrolling participants,…
ALAGILLE SYNDROME
NewsResearchers develop new way to recognize Alagille-causing mutations
A team of researchers has developed a new screening system to identify previously unrecognized mutations as the likely cause of Alagille syndrome. In a…
HEPATITIS
NewsFDA gives green light to trial of HBV treatment GIGA-2339
The U.S. Food and Drug Administration (FDA) has given Gigagen the go-ahead to start clinical testing of GIGA-2339, its experimental treatment for hepatitis B…
CHOLANGITIS
NewsCM-101 shows signs of targeting all PSC aspects in Phase 2 trial
The experimental therapy CM-101 is generally safe and results in signs of improvement in liver health and health of the ducts that transport the…
CHOLESTASIS
NewsPFIC treatment IN016 gets FDA orphan drug status
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IN016, an experimental therapy Innorna is developing for progressive familial…
FATTY LIVER DISEASE
NewsPemvidutide seen to lower liver fat in MASLD patients in Phase 1 trial
Pemvidutide, Altimmune’s experimental therapy, significantly reduced liver fat and inflammation, as well as body weight, among overweight or obese people with metabolic dysfunction-associated…
Recent Posts
- Living with MASH reminds me to avoid making assumptions
- Particles in grilled meats may trigger liver disease, mouse study finds
- Supporting my oldest son, who’s growing up with a chronically ill sibling
- Human trial testing gene silencing injection therapy for MASH kicks off
- Blood bile acids predict liver outcomes in Alagille syndrome children: Study